Mini Liver

Accelerating drug discovery

1 in 1500

In born errors of liver metabolism (IEM) affects 1 in 1500 live births

50 %

Nearly 50% of all acute liver failure and 30-40% of all chronic liver disease, in children are due to IEM

10 %

10% of world’s population has chronic liver disease, including 25 million Americans

70 %

Liver transplantation is now a routine procedure with more than 70% patients show five-year survival

2500

There is a shortage of grafts: causing more than 2500 patients to die per year, while awaiting a graft

90 %

Mortality in India more than 90% due to lack of transplant options

Hepatotoxicity and DMPK studies

3D Liver Tissue

Drug metabolism and pharmacokinetics (DMPK) has become one of the core disciplines in the drug discovery process that focuses on evaluating the safety and efficacy of the drug candidates. Sub-optimal DMPK profile has been one of the major reasons for the attrition of drug at the clinical phase of the trial indicating the poor ADME properties (Absorption, Digestion, Metabolism and Excretion) and drug-drug interaction (DDI). Our 3D hepatocyte spheroids are suitable for long-term culture with enhanced hepatocyte phenotype like albumin secretion, CYP activity for testing drug induced toxicity and metabolism

mini-liver1 — CYP3A4 expression in PHH (primary human hepatocyte) spheroid

Multicellular primary liver organoid suitable for modeling steatosis and fibrosis. Hepatocytes – red, stellate cells – green, nucleus – blue

Organoid model for NASH drug discovery

3D Liver Tissue

Pandorum’s 3D organoids containing multi-lineage cell types recapitulate the native microenvironment with parenchymal hepatocytes co-cultured with kupffer cells, hepatic stellate cells and liver endothelial cells. These organoids are induced to recapitulate the complex disease phenotype including steatosis, inflammation and fibrosis involving multiple cell-cell cross talks. The above model would mimic the in-vivo disease physiology and thus increases the accurate prediction of drug effect during NASH drug discovery. Our organoid model is suitable for long-term culture with more than two weeks of assay window for the dosing of potential anti-steatosis, anti-inflammatory and anti-fibrotic drugs

Implantable vascularized organoids for Bio-artificial liver

Mini Liver

3D cultured organoids are not only emerging as the platform for drug screening and disease modeling, but also have a potential in regenerative medicine and therapy. We, at Pandorum, aim to develop 3D bio-printed vascularized mini-organ or organ patches with the potential of engrafting on to the host tissue upon transplantation. Currently we’re developing a prototype for the same.